Curis, Debiopharm announce initiation of Phase Ib expansion study of Debio 0932

Curis and Debiopharm Group announced that Debiopharm has begun treating patients in a Phase Ib clinical trial of Heat Shock Protein 90, or HSP90, inhibitor Debio 0932. Debiopharm recently successfully completed a Phase Ia dose escalation study with Debio 0932 and has indicated that it expects to initiate a combination Phase I/II study in non-small cell lung cancer patients in Q2 of 2012.